Regentis Biomaterials Advances Toward Key Milestones for Simplified Cartilage Repair Platform
Regentis Biomaterials Ltd. is progressing its GelrinC hydrogel implant toward European commercialization and U.S. FDA submission, targeting a $3 billion market for knee cartilage repair with a cell-free, single-step procedure.
Regentis Biomaterials Ltd. (NYSE American: RGNT) is advancing its GelrinC® hydrogel implant toward key commercial milestones, positioning the company to address a significant unmet need in knee cartilage repair. The cell-free, off-the-shelf implant is designed to simplify the procedure through a single-step, approximately 10-minute intervention, offering a potential alternative to traditional microfracture and complex cell-based therapies.
GelrinC® targets an estimated $3 billion U.S. market encompassing roughly 470,000 annual knee cartilage repair cases, where no approved off-the-shelf regenerative solution currently exists. Clinical data have shown approximately 100% greater pain improvement versus microfracture, alongside MRI-confirmed regeneration of near-native cartilage and durable multi-year outcomes. The product has already secured CE Mark approval in Europe and is currently progressing through a pivotal U.S. Phase III trial that is more than 50% enrolled.
According to the company, upcoming catalysts include potential European commercialization, completion of the pivotal study, and eventual FDA submission. These milestones could significantly impact the orthopedic treatment landscape by providing a simpler, more accessible regenerative option for patients with damaged knee cartilage.
Regentis Biomaterials is a regenerative medicine company dedicated to developing innovative tissue repair solutions. Its Gelrin platform technology, based on synchronized, degradable hydrogel implants, aims to regenerate damaged or diseased tissue including inflamed cartilage and bone. The lead product, GelrinC®, is eroded and resorbed in the knee, allowing surrounding cells to regenerate cartilage in a controlled and synchronous process.
For more information, view the full corporate profile at https://ibn.fm/bpPp6. The latest news and updates relating to RGNT are available in the company’s newsroom at https://ibn.fm/RGNT.